North AP market grew the highest followed by Jharkhand and south AP market
The Indian pharmaceutical market (IPM) clocked Rs 8047 crores in April 2015. It registered a growth of 17.2 per cent in the same month. Amongst the top 10, Cipla grew by 25.1 per cent followed by Macleods at 18.9 per cent and Sun at 18.4 per cent. 26 corporates have crossed the growth of IPM for the month of April 2015 amongst top 50. Amongst the top 50 corporate, Akumentis has the highest growth of 38.2 per cent followed by Allergan at 35.5 per cent and MSD at 34.9 per cent. 41 corporates showed growths of more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporate, Glenmark has the highest growth of 30.1 per cent followed by Torrent at 28.7 per cent and Aristo at 26.9 per cent. Amongst the 40-50 ranked corporates, Allergan has the highest growth at 35.5 per cent followed by Albert David at 34.2 per cent and Hetero at 27.2 per cent.
Amongst the 51-60 ranked corporate, Centaur grew at 44.7 per cent followed by Eli Lilly at 42.3 per cent and Troikaa at 40 per cent. Amongst the 61-70 ranked corporate, Fresenius Kabi grew at 65.6 per cent followed by Boehringer grew by 86.2 per cent followed by Serdia at 31.9 per cent. Torrent entered the Rs 2000-crore club, JBCPL and Akumentis entered the Rs 500-crore club, BI entered the Rs 200-crore club, Dr John’s in the Rs 50-crore club as on April MAT 2015.
Indian companies have grown at 17.1 per cent versus 17.5 per cent for MNCs in April 2015. Amongst the top 50 in MNCs, Allergan grew by 35.5 per cent followed by MSD at 34.9 per cent and Merck at 30.6 per cent. Under the Non-NLEM category, Indian companies grew at 18.3 per cent whereas MNCs grew at 18.8 per cent.
The DPCO containing molecules market grew at 11.1 per cent whereas the non-DPCO market grew by 18.4 per cent and Non -Sch Para 19 Market at 11.9 per cent resulting in an overall growth of 17.2 per cent for April 2015. NLEM and Non – NLEM category showed unit growth at 5.3 per cent and 9.6 per cent respectively. The Non-Sch Para 19 market grew at 9.6 per cent from units perspective. The DPCO 2013 portfolio for Pfizer grew at 16.7 per cent, Ranbaxy 17.3 per cent, GSK at 12.2 per cent and Abbott 13.5 per cent.
From therapy perspective, eight therapies have outgrown the IPM growth. Respiratory market grew at 17.8 per cent, gastrointestinal market grew at 20.3 per cent, pain and analgesics market grew at 15.4 per cent whereas anti-infectives grew at 12.8 per cent. The anti-diabetic market grew at 25.8 per cent and cardiac at 16.2 per cent in chronic business. Derma market grew by 22.2 per cent and urology market at 28.5 per cent.
From regional perspective, 14 regions have outgrown the IPM growth. North AP market grew the highest at 31.1 per cent followed by Jharkhand market at 27.8 per cent and South AP Market at 25.2 per cent. One region had negative growth in April 2015. Amoxycillin + Clavulanic Acid Market grew at 16.7 per cent whereas Glimepiride + Metformin grows at 15.9 per cent at number two.
The markets of paracetamol grew at 18.9 per cent, Atorvastatin 12.7 per cent, Probiotic Microbes at 12.2 per cent, Cefixime 19.2 per cent, Pantoprazole 22.7 per cent, Montelukast + Levocetrizine at 25.3 per cent, Glimepiride + Metformin + Pioglitazone at 19.6 per cent, Vitamin-D at 35.9 per cent, Hydroquinone + Mometasone + Tretinoin at 16.4 per cent, Voglibose + Metformin + Glimepiride at 58.1 per cent, Rosuvastatin at 21.4 per cent, Protein Supplements at 20.2 per cent, Azithromycin at 14.4 per cent.
Glycomet – GP becomes the No 1 Brand for Apr-15 with a value of Rs 29.53 crores and growth of 18.6 per cent with a MAT Value of Rs 299 crores. Lantus grew at 37.3 per cent, Monocef at 36.6 per cent, Glycomet-GP grew at 33.3 per cent, Dexorange at 34.7, Augmentin at 29.7 per cent and Becosules at 29.1 per cent amongst the top 10 Brands.
Few brands which have gained ranks include Pentaxim (+1312), Janumet (+71), Betnovate –C (+60), Januvia (+58), Shelcal (+57), Panderm Plus (+49), Istamet (+35), Clexane (+31), Spasmo Proxyvon Plus (+29), Magnex (+28), Huminsulin (+26), Pantocid D SR (+25), Dolo (+22), Omez (+17), Zifi (+11), Zoryl –M (+10), Rhoclone (+9), Orofer – XT (+8), Storvas (+8), amongst top 100 Brands over April 2014.
A total of 162 brands and 300 SKUs were launched in April 2015. Top new brands for April are Sovihep, Eliquis and Revital-H.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage
For more information, visit http://www.aiocd.net